Abstract
e16008Background: Up to 40% of patients treated with intravesical agents for non-muscle invasive bladder cancer (NMIBC) will recur. Our lab has previously demonstrated the feasibility of mTOR inhib...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
